Pharmaceutical

Meitheal partners with Chinese company for US licencing of insulin biosimilars

The licence grants Meitheal marketing rights for insulin aspart, lispro, and glargine following FDA approval.

Sep 21, 2023 - 20:00
Meitheal partners with Chinese company for US licencing of insulin biosimilars
The licence grants Meitheal marketing rights for insulin aspart, lispro, and glargine following FDA approval.
Read the original article

Tags:

Previous Article

STAT+: Pear’s shadow effect: Data from a Medicaid digital health experiment does...

Next Article

Evaxion partners with Afrigen Biologics to develop mRNA gonorrhea vaccine

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Medicare puts out new details for covering the Alzheimer’s drug Leqembi, as the health system readies for potential approval

STAT+: Medicare puts out new details for covering the A...

Jun 22, 2023

How hybrid models and tech are shaping the future of clinical research 

How hybrid models and tech are shaping the future of cl...

Nov 3, 2024

Reeves’ 2024 budget promises life sciences investment

Reeves’ 2024 budget promises life sciences investment

Nov 1, 2024